AKYLA/ Financials
MarketsScreenerFinancialsResearchChat
Equity / BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)
Denali Therapeutics Inc. Common Stock
XNAS · usd
SIC 2836 · BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)
FIGI BBG008P7F878
18.41▼ 0.25 (-1.34%)
As of 2026-10-23
Price / Volume
Valuation
Market Cap
Enterprise Value
Trailing P/E
—
Price / Sales
EV / Revenue
EV / EBITDA
Financial Highlights
Revenue (TTM)
Net Income (TTM)
EBITDA
Diluted EPS (TTM)
EBITDA Margin
Net Debt
Trading Information
Previous Close
18.66
Day's Range
18.01 – 18.50
52-Week Range
13.75 – 27.30
Volume
1.0M
Avg Volume
1.9M
Share Statistics
Shares Outstanding
Employees
503
Exchange
XNAS
Listed
2017-12-08
Share count as of July 31, 2026

Denali Therapeutics Inc. Common Stock (DNLI) Financial Statements

View
Income Statement
Detail
Standard
Period
Quarterly
Loading Income Statement…
Key questions about Denali Therapeutics Inc. Common Stock (DNLI)
What is Denali Therapeutics Inc. Common Stock's Market Cap?
Denali Therapeutics Inc. Common Stock's Market Cap is $2.9B, based on as-reported figures from SEC (XBRL) filings.
What is Denali Therapeutics Inc. Common Stock's Enterprise Value?
Denali Therapeutics Inc. Common Stock's Enterprise Value is $2.2B, based on as-reported figures from SEC (XBRL) filings.
What is Denali Therapeutics Inc. Common Stock's Price / Sales?
Denali Therapeutics Inc. Common Stock's Price / Sales is 816.5×, based on as-reported figures from SEC (XBRL) filings.
What is Denali Therapeutics Inc. Common Stock's EV / Revenue?
Denali Therapeutics Inc. Common Stock's EV / Revenue is 620.9×, based on as-reported figures from SEC (XBRL) filings.
What is Denali Therapeutics Inc. Common Stock's EV / EBITDA?
Denali Therapeutics Inc. Common Stock's EV / EBITDA is n/m, based on as-reported figures from SEC (XBRL) filings.
What is Denali Therapeutics Inc. Common Stock's Revenue (TTM)?
Denali Therapeutics Inc. Common Stock's Revenue (TTM) is $3.6M, based on as-reported figures from SEC (XBRL) filings.
What is Denali Therapeutics Inc. Common Stock's Net Income (TTM)?
Denali Therapeutics Inc. Common Stock's Net Income (TTM) is -$511.5M, based on as-reported figures from SEC (XBRL) filings.
What is Denali Therapeutics Inc. Common Stock's EBITDA?
Denali Therapeutics Inc. Common Stock's EBITDA is -$530.5M, based on as-reported figures from SEC (XBRL) filings.
What is Denali Therapeutics Inc. Common Stock's Diluted EPS (TTM)?
Denali Therapeutics Inc. Common Stock's Diluted EPS (TTM) is -3.20, based on as-reported figures from SEC (XBRL) filings.
What is Denali Therapeutics Inc. Common Stock's EBITDA Margin?
Denali Therapeutics Inc. Common Stock's EBITDA Margin is -14718.9%, based on as-reported figures from SEC (XBRL) filings.
Akyla / Financials · DNLIAs-filed SEC (XBRL) data
Showing the most recent year. Subscribe for full statement history.
Income Statement(in thousands of USD, except per-share data)
Source: Akyla.ai
Line ItemJun 30, 2026Mar 31, 2026Dec 31, 2025Sep 30, 2025Jun 30, 2025Mar 31, 2025Dec 31, 2024Sep 30, 2024Jun 30, 2024Mar 31, 2024Dec 31, 2023Sep 30, 2023Jun 30, 2023Mar 31, 2023Dec 31, 2022Sep 30, 2022
Revenue:
Total revenue———
YoY growth————
Operating expenses:
Cost of goods sold———
Research and development
Selling, general and administrative———
Intangible asset amortization———
Total operating expenses
% of revenue3722.1%———
Loss from operations
% of revenue-3622.1%———
Interest and other income, net
Net loss
% of revenue-3539.2%———
Net loss per share, basic (usd per share)
Net loss per share, diluted (usd per share)